Jonah Houts stands at the forefront of a shifting paradigm in American healthcare, serving as the vice president of account management, contracting, and strategy at Walgreens Specialty Pharmacy. With a career dedicated to deconstructing the labyrinthine structures of pharmacy benefit management, he provides a rare, transparent look into why drug costs continue to spiral despite the availability of generic alternatives. His expertise is grounded in the reality of high-stakes negotiations where a single oversight can cost a plan sponsor millions, making him an essential voice for payers navigating the increasingly consolidated world of specialty medicine.
The following discussion explores the structural flaws in traditional pharmacy benefit models and the “six-figure blind spots” that often go unnoticed in annual trend reports. We delve into the critical role of independence in pharmacy partnerships, the financial mechanics of cost-plus pricing, and the profound impact that proactive patient care has on the total cost of therapy. Through the lens of clinical outcomes and geographic accessibility, the conversation highlights how the future of specialty pharmacy must pivot toward a model that prioritizes the patient’s experience over corporate integration.
How do six-figure price tags for generic specialty drugs manage to slip through the cracks of modern healthcare plans without being flagged by internal systems?
The reality is that specialty drug pricing is frequently folded inside much larger, incredibly complex deals, which creates a significant lack of visibility for the payer. We recently saw a staggering case where a state-sponsored plan was charged $138,000 a year for a generic cancer drug that actually carried a wholesale cost of only $14,000. Because the system wasn’t designed to catch these discrepancies, that massive markup was simply absorbed into the broader trend report, becoming an invisible burden on the sponsor’s budget. When these costs are hidden within bundled contracts, what you can’t see, you simply cannot manage, and these “six-figure stories” become all too common. It takes a dedicated, transparent approach to strip away those layers of complexity and reveal the true economics of what is being paid for at the pharmacy counter.
With the three largest pharmacy benefit managers now overseeing roughly 80% of all U.S. prescription drug claims, how has this level of consolidation changed the way payers evaluate their pharmacy benefits?
This massive consolidation has created an environment where a single corporate parent often owns the insurer, the pharmacy benefit manager, and the dispensing pharmacy all at once. While this might suggest efficiencies of scale on paper, it actually makes it much harder for a payer to see how individual components of the benefit are performing or contributing to the bottom line. When the entity negotiating the price is the same one dispensing the medication and insuring the patient, the incentive for transparency can sometimes be outweighed by internal corporate goals. Payers are beginning to realize that this level of integration can obscure the full picture, leaving them unable to tell if they are getting a fair deal on pricing or if rebates are truly aligned with their long-term cost-reduction goals.
Why is being “payer-agnostic” considered such a significant advantage for an independent specialty pharmacy partner in today’s market?
Independence allows us to operate without being tethered to specific rebate relationships or proprietary formularies that might not serve the plan sponsor’s best interest. Because we are payer-agnostic, we can build and administer a specialty pharmacy benefit that works exclusively for the client, sourcing the best possible price for every drug without outside interference. This independence eliminates the conflicting incentive dynamics often found in bundled arrangements where retail, mail order, and rebate management are all packaged together. It provides plan sponsors with a clear, direct view of their spend, ensuring that every dollar is accounted for and that the pharmacy’s goals are perfectly aligned with the payer’s financial health and the patient’s clinical success.
Can you explain how the “cost-plus” pricing model functions as a solution to the percentage-based markups that often inflate specialty drug costs?
Our approach to cost-plus pricing is designed to be a “plug-and-play” solution where the plan sees exactly what is being paid for a drug, paired with a transparent, flat dispensing fee. This structure is vital because it eliminates those percentage-based markups that can cause a $1,000 drug to suddenly morph into a $10,000 expense just because a specific contract guarantee allowed it to happen. We maintain a cycle of constant reporting throughout the entire process so that no one is surprised by a sudden spike in the cost of a therapy. By moving away from opaque pricing guarantees and toward a model of total visibility, we ensure that the price on the bill reflects the actual value and cost of the medication rather than an arbitrary figure designed to meet a corporate margin.
Why do you suggest that the most significant costs associated with specialty drugs aren’t actually found on the pharmacy bill?
The most devastating costs often don’t stem from the price of the medication itself, but rather from the clinical fallout when a drug isn’t taken correctly, consistently, or at all. Every missed dose or unmanaged side effect represents a potential crisis that can lead to avoidable hospitalizations, unnecessary switches to even more expensive therapies, and significant drug waste. We see this most clearly in complex fields like oncology, where even a small gap in adherence can force a dose reduction or cause a patient to drop off therapy entirely, leading to rapid clinical decline. These complications are “hidden” costs because they manifest as expensive emergency room visits or flares in chronic inflammatory diseases rather than as a line item on a pharmacy trend report.
In what ways does the Specialty 360 model transform the patient’s journey from the moment a prescription is first received?
Specialty 360 is our patient-facing care model that shifts the focus from reactive dispensing to proactive, patient-centered clinical management. From the very first moment a prescription arrives, our dedicated disease-specific teams are working on benefits verification, prior authorization, and patient education to prevent any delays in starting therapy. We use a proprietary clinical platform to anticipate potential barriers—such as affordability concerns or confusion about side effects—before they escalate into a reason for non-adherence. By providing this continuous engagement, we ensure that therapy stays on track, which creates immense value for payers by preventing the costly complications that arise when patients feel overwhelmed or unsupported.
How does having more than 250 community-based specialty pharmacies and thousands of retail locations change the “last mile” of care for someone with a rare disease?
Physical presence is a critical component of care because it allows us to meet patients exactly where they are, whether that is near their home or their doctor’s office. With 70% of providers located within 25 miles of one of our community-based specialty pharmacies, we are embedded in the local care ecosystems, allowing for in-person support and personalized clinical programs that you just can’t get through a mail-order-only model. Furthermore, the ability to ship specialty medications to any of our more than 8,000 retail locations nationwide provides a level of omnichannel access that is vital for same-day needs or complex storage requirements. This geographic reach ensures that a patient’s treatment isn’t interrupted by logistical hurdles, providing a sense of security and reliability that is essential when managing a life-threatening or rare condition.
What is your forecast for the specialty pharmacy industry over the next few years?
I believe we are entering an era where the industry will be forced to move beyond the narrow focus of drug pricing and toward a more holistic, patient-centered approach. As specialty medications become increasingly complex and expensive, the demands on the pharmacy ecosystem will intensify, making the visibility of patient-level insights more valuable than ever for managing long-term outcomes. We will likely see a significant shift away from the “black box” of bundled PBM services as payers demand more transparency and independent partners who can prove they are actually improving patient health. Ultimately, you can build all the complex and rigorous systems you want around drug spend, but the industry is realizing that if the model isn’t taking care of the patient at the center of it all, the entire financial and clinical structure eventually falls apart.
